This is promotional content, intended for UK healthcare professionals only. This webpage has been developed and funded by the Bristol-Myers Squibb / Pfizer Alliance.
Click here to view ELIQUIS® (apixaban) prescribing and adverse event reporting information.
This section addresses the management of patients with suspected VTE, including:
• Awareness of signs and symptoms of VTE
• Investigations for a suspected DVT
• Investigations for a suspected PE
Adverse events should be reported. Reporting forms and information can be found via United Kingdom – The yellow card scheme at www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Bristol-Myers Squibb via email@example.com or 0800 731 1736 (United Kingdom).
DVT=Deep Vein ThrombosisMHRA=Medicines and Healthcare products and Regulatory AgencyPE=Pulmonary EmbolismVTE=Venous Thromboembolism
Job code: 432-GB-2100109
Date of preparation: September 2021
YOU ARE ABOUT TO LEAVE THIS WEBSITE
This link takes you to a third party website that is part of the Bristol-Myers Squibb Group and Pfizer Group. The Alliance (Bristol Myers Squibb Group and Pfizer Group) recommends that you check whether it is suitable for you as per its intended audience and the applicable laws and regulations before accessing it. If you wish to continue, click ‘Continue’, otherwise click ‘Stay on this site’.